Horizon Pharma plc (HZNP) : Wednesdays money flow points at investors jumping to buy the stock on the weakness of price. $0.3 million worth of transactions were on upticks, whereas, the downticks accounted for $0.03 million worth of transactions. The net money flow was a positive $0.27 million and the uptick to downtick ratio was 9.43. The net money flow into the stock was $0.26 million. The lack of interest in trading on downticks shows that the investors dont want to sell their holdings. The upticks accounted for $0.26 million of the total block trades, indicating continued buying interest on weakness, which bodes well for the future of the stock. Horizon Pharma plc (HZNP) was trading at $18.82, down $0.04 during day. The stock slid -0.21% over the previous days close. For the week, the stock recorded -3.14% over the previous weeks close.
Horizon Pharma plc has lost 2.03% in the last five trading days and dropped 0.32% in the last 4 weeks. Horizon Pharma plc is up 12.12% in the last 3-month period. Year-to-Date the stock performance stands at -13.34%.
Horizon Pharma plc (HZNP) has an average broker rating of 1.57, which is interpreted as a Buy, as rated by 7 equity analysts. Nonetheless, 5 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 2 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold.
Horizon Pharma plc (NASDAQ:HZNP): stock was range-bound between the intraday low of $18.52 and the intraday high of $19.0289 after having opened at $18.97 on Wednesdays session. The stock finally closed in the red at $18.97, a loss of -0.42%. The stock remained in the red for the whole trading day. The total traded volume was 2,432,501 shares. The stock failed to cross $19.0289 in Wednesdays trading. The stocks closing price on Thursday was $18.86.
Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a specialty biopharmaceutical company focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products that address unmet medical needs. The Company markets a portfolio of products in arthritis, inflammation and orphan diseases. The Companys the United States marketed products are ACTIMMUNE (interferon gamma-1b), DUEXIS (ibuprofen/famotidine), PENNSAID (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%), RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium). The Company developed DUEXIS and RAYOS/LODOTRA, has the United States rights to VIMOVO, has the United States rights to ACTIMMUNE and has the United States rights to PENNSAID 2%.